Cancer-specific outcomes for prostate cancer patients who had prebiopsy prostate MRI.

ABSTRACT:

Purpose

We characterized population-level cancer-specific outcomes for prostate cancer patients based on use of prebiopsy prostate MRI.

Methods

Using SEER-Medicare claims, we identified men diagnosed with localized prostate cancer from 2010-2015 and prostate-specific antigen (PSA) < 20 ng/mL. Primary exposure was prebiopsy prostate MRI prior to diagnosis (i.e., CPT 72197 linked to urology-specific diagnosis). Outcomes included diagnosis of Grade Group 2+ disease on biopsy and proportion treated with prostatectomy. We assessed those treated with prostatectomy and evaluated association with prebiopsy MRI and grade concordance between biopsy and prostatectomy. We estimated adjusted odds ratios with multivariable regression after accounting for other factors (e.g., age, year, PS

SUBMITTER: Li J 

PROVIDER: S-EPMC8807787 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature